Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-12-30 Sale |
2024-12-30 7:48 pm |
GENELUX Corp | GNLX | Tyree James L Director |
3,460 | $2.46 | $8,512 | 45,791 (Direct) |
View |
| 2024-12-16 Sale |
2024-12-18 4:35 pm |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
14,315 | $2.34 | $33,497 | 37,372 (Direct) |
View |
| 2024-12-16 Sale |
2024-12-18 4:35 pm |
GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer |
2,103 | $2.34 | $4,921 | 40,802 (Direct) |
View |
| 2024-12-16 Sale |
2024-12-18 4:35 pm |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
2,510 | $2.34 | $5,873 | 16,322 (Direct) |
View |
| 2024-12-16 Sale |
2024-12-18 4:35 pm |
GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development |
6,300 | $2.34 | $14,742 | 14,653 (Direct) |
View |
| 2024-09-12 Sale |
2024-09-13 6:22 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
64,857 | $2.647 | $171,678 | 3,413,581 (Indirect) |
View |
| 2024-09-11 Sale |
2024-09-12 8:40 pm |
GENELUX Corp | GNLX | Tyree James L Director |
1,730 | $2.6005 | $4,499 | 47,521 (Direct) |
View |
| 2024-09-09 Sale |
2024-09-11 6:23 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
75,143 | $2.6165 | $196,609 | 3,478,438 (Indirect) |
View |
| 2024-09-03 Sale |
2024-09-06 5:08 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
42,818 | $2.0929 | $89,614 | 3,553,581 (Indirect) |
View |
| 2024-08-28 Sale |
2024-08-30 7:58 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
265,552 | $2.0878 | $554,411 | 3,596,399 (Indirect) |
View |
| 2024-08-23 Sale |
2024-08-27 7:23 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
91,630 | $2.1857 | $200,278 | 3,861,951 (Indirect) |
View |
| 2024-06-24 Sale |
2024-07-08 4:30 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
6,849 | $2.12 | $14,520 | 10,869 (Direct) |
View |
| 2024-06-24 Sale |
2024-07-08 4:30 pm |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
5,496 | $2.12 | $11,652 | 19,388 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-14 Option Award |
2025-04-17 4:58 pm |
N/A N/A |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
4,172 | $0 | 36,019 (Direct) |
View |
| 2025-03-14 Option Award |
2025-04-17 4:57 pm |
N/A N/A |
GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development |
13,350 | $0 | 57,003 (Direct) |
View |
| 2025-03-14 Option Award |
2025-04-17 4:56 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
13,350 | $0 | 53,219 (Direct) |
View |
| 2025-03-14 Option Award |
2025-04-17 4:55 pm |
N/A N/A |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
10,708 | $0 | 52,096 (Direct) |
View |
| 2025-03-14 Option Award |
2025-04-17 4:54 pm |
N/A N/A |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
30,339 | $0 | 202,211 (Direct) |
View |
| 2025-01-31 Option Award |
2025-02-03 6:16 pm |
N/A 2035-01-30 |
GENELUX Corp | GNLX | Pulisic Matthew Chief Financial Officer |
275,000 | $0 | 275,000 (Direct) |
View |
| 2024-08-01 Option Award(A) |
2024-12-31 1:20 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Thomas John Director |
50,469 | $0 | 50,469 (Direct) |
View |
| 2024-08-01 Option Award(A) |
2024-12-31 1:20 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Mirabelli Mary Director |
50,469 | $0 | 50,469 (Direct) |
View |
| 2024-08-01 Option Award(A) |
2024-12-31 1:20 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Smither John W Director |
50,469 | $0 | 50,469 (Direct) |
View |
| 2024-08-01 Option Award(A) |
2024-12-31 1:20 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Tyree James L Director |
50,469 | $0 | 50,469 (Direct) |
View |
| 2024-12-18 Option Award |
2024-12-20 8:49 pm |
N/A 2034-12-17 |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
36,625 | $0 | 52,947 (Direct) |
View |
| 2024-12-18 Option Award |
2024-12-20 8:48 pm |
N/A 2034-12-17 |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
52,000 | $0 | 71,388 (Direct) |
View |
| 2024-12-18 Option Award |
2024-12-20 8:46 pm |
N/A 2034-12-17 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
68,000 | $0 | 78,869 (Direct) |
View |
| 2024-12-18 Option Award |
2024-12-20 8:45 pm |
N/A 2034-12-17 |
GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development |
68,000 | $0 | 82,653 (Direct) |
View |
| 2024-12-18 Option Award |
2024-12-20 8:44 pm |
N/A 2034-12-17 |
GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer |
98,175 | $0 | 138,977 (Direct) |
View |
| 2024-12-18 Option Award |
2024-12-20 8:43 pm |
N/A 2034-12-17 |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
317,500 | $0 | 354,872 (Direct) |
View |
| 2024-10-18 Option Award |
2024-10-21 5:05 pm |
N/A 2034-10-17 |
GENELUX Corp | GNLX | Scigalla Paul Chief Medical Officer |
33,332 | $0 | 33,332 (Direct) |
View |
| 2024-08-01 Option Award |
2024-08-05 6:37 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Tyree James L Director |
90,010 | $0 | 99,720 (Direct) |
View |
| 2024-08-01 Option Award |
2024-08-05 6:36 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Mirabelli Mary Director |
90,010 | $0 | 102,470 (Direct) |
View |
| 2024-08-01 Option Award |
2024-08-05 6:35 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Thomas John Director |
90,010 | $0 | 555,970 (Direct) |
View |
| 2024-08-01 Option Award |
2024-08-05 6:34 pm |
N/A 2034-07-31 |
GENELUX Corp | GNLX | Smither John W Director |
90,010 | $0 | 103,180 (Direct) |
View |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
34,584 | $0 | 50,207 (Direct) |
View |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer |
5,072 | $0 | 38,428 (Direct) |
View |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
2,723 | $0 | 18,144 (Direct) |
View |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development |
15,218 | $0 | 20,953 (Direct) |
View |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
15,218 | $0 | 10,869 (Direct) |
View |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
12,206 | $0 | 19,388 (Direct) |
View |